Disrupting cancer through SurVaxM immunotherapy
At MimiVax, our mission is to disrupt cancer. We are dedicated to improving survival and sending hope to cancer patients
SurVaxM is a first-of-its-kind, peptide mimic immunotherapeutic vaccine (immunotherapy) that targets survivin, a cell-survival protein present in nearly all glioblastomas and many other cancers. It is engineered to recognize survivin-expressing cancer cells and stimulate a patients’ own immune response to control tumor growth.
While vaccines are typically thought of as ways to prevent diseases, vaccines can also be used in a therapeutic mode as an immunostimulant (e.g., to treat cancer). SurVaxM is delivered through simple subcutaneous injection to prevent tumor recurrence.
OUR MISSION
To disrupt cancer with innovative immunotherapies
SurVaxM is currently being evaluated in:
-Phase 2b: adult newly diagnosed glioblastoma
-Phase 1: SurVaxM + lenalidomide in multiple myeloma
-Phase 2: Metastatic NeuroEndocrine Tumors (NET)
-Phase 1: Pediatric relapsed/recurrent high grade gliom2
Clinical trials
0
Cancers: GBM, NET's, Multiple Myeloma, & Pediatric Brain Tumors
0
Patient Participants
265
Doses
1995
News and Events
“Phase IIa Study of SurVaxM plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma”
“Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM”
“Developing a new cancer immunotherapy, SurVaxM from bench to bedside”
MimiVax, Inc., today announced that its now fully enrolled Phase 2b clinical trial of SurVaxM in glioblastoma, [SURVIVE] (NCT05163080), has successfully progressed following the first interim analysis of trial data. The analysis has provided valuable insights that support the continued advancement of the trial.
- Ongoing clinical trial of SurVaxM in glioblastoma [SURVIVE] has successfully progressed following an interim analysis of trial data.
- The fully enrolled Phase 2b SURVIVE study will continue as planned to collect more data.
February 12, 2025
Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication
This phase 2 trial is the result of years of careful, collaborative science between MimiVax, Roswell Park Comprehensive Cancer Center, and the neuroendocrine tumor community.
The phase 2 trial builds on Roswell Park’s previous NET research. Importantly, the phase 1 study demonstrated that SurVaxM was safe and generated measurable immune responses in NET patients.
May 5, 2026
The current study found that 51% of nGBM patients receiving SurVaxM had survived at least 2 years .
MimiVax is pleased to announce the published manuscript of the now completed Phase 2A study of SurVaxM, in newly diagnosed glioblastoma (nGBM) in the Journal of Clinical Oncology.
A follow-up Randomized, Blinded Placebo-Controlled Phase 2B Clinical trial of SurVaxM for nGBM is in progress.
Manuscript available at:
JCO.22.00996
JCO.22.00996
December 15, 2022
Please help support the 2024 Empire State Ride & Team Danielle (Devlin) Casucci!
This year’s Empire State Ride marks a milestone as it is the ride’s 10-year anniversary, 9 years of which our own VP of Clinical Operations, Danielle Casucci has participated. Danielle and the team will ride bicycles 500+ miles from New York City to Niagara Falls, over the course of a week, to raise money for cancer research at Roswell Park, specifically designated toward the SurVaxM trial.
MimiVax
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
PartnerING
MimiVax is improving outcomes and quality of life for those suffering from devastating diseases as well as strengthening the biomedical startup ecosystem of Buffalo, New York.
Pipeline
We’re exploring new ways of stimulating the immune system to fight cancer cells leveraging our proprietary survivin-targeting technology.
Clinical Trials
SurVaxM is presently being studied in glioblastoma (newly diagnosed and recurrent), multiple myeloma and neuroendocrine tumors (NET).
Partner with us
MimiVax is a privately held, clinical-stage biotechnology company that was formed in 2012 from Roswell Park Comprehensive Cancer Center. This was quickly followed by a prestigious award from the American Cancer Society, and support from the Roswell Park Alliance Foundation enabling clinical studies of SurVaxM for glioblastoma. If you are an investor interested in MimiVax, please reach out via the contact form below.
Contact us
To view a listing of investigational clinical trials open to patient enrollment that include SurVaxM, please visit clinicaltrials.gov.
For general inquiries: info@mimivax.com
Help accelerate the pace of SurvaxM clinical trials
The Roswell Park Alliance Foundation is the charitable arm of Roswell Park Comprehensive Cancer Center, where SurVaxM research started. Donations to the Alliance Foundation helped make early phase SurVaxM clinical studies possible and will continue to accelerate the pace and scope of future SurVaxM clinical trials. Please follow this link to make a potentially life changing contribution to this critical effort.